Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Dementia often goes undetected in hospital settings, where cognitive assessments are challenging due to illness severity and delirium. This study aimed to (1) evaluate the accuracy of the Clinical Dementia Rating (CDR), based solely on knowledgeable informant reports, for detecting preexisting dementia and cognitive impairment in hospitalized patients compared to a gold-standard diagnosis, (2) and compare its performance to the 16-item Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE-16).

Methods: This cross-sectional study assessed consecutive patients aged ≥ 65 admitted to inpatient units from five hospitals in Brazil. The informant-based CDR was administered to knowledgeable informants within 48 h of admission, capturing patients' cognitive status 3 months before hospitalization to avoid the influence of acute cognitive impairments. Blinded experts provided a gold standard clinical diagnosis of dementia or cognitive impairment no dementia (CIND) based on a 90-min comprehensive assessment, including a standardized neuropsychology battery. Areas under the curve (AUC) examined diagnostic accuracy.

Results: Of 65 participants (mean age = 79.4 years; women = 54%), 34% had dementia and 32% had CIND. Compared to the gold standard, the informant-based CDR showed excellent diagnostic accuracy for detecting dementia (AUC = 0.92; 95% confidence interval [CI] = 0.86-0.98) and cognitive impairment (AUC = 0.93; 95% CI = 0.88-0.98), with a cutoff of ≥ 1 showing 98% specificity for dementia and a cutoff of ≥ 0.5 showing 98% sensitivity for cognitive impairment. Compared to the IQCODE-16, the informant-based CDR had similar performance in detecting dementia and a nonsignificant slight advantage in identifying cognitive impairment (AUC = 0.93 vs. 0.84, p = 0.069), reducing unrecognized cognitive impairment based on medical record documentation from 70% to 2%.

Conclusions: Informant-based CDR is a valid and efficient tool for detecting dementia and cognitive impairment in hospitalized older adults, supporting early diagnosis and guiding multidisciplinary interventions in acute care. Its use in routine hospitals may help clinicians reduce undetected cognitive impairment, enhance decision making, and improve patient care.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12353518PMC
http://dx.doi.org/10.1111/jgs.19494DOI Listing

Publication Analysis

Top Keywords

cognitive impairment
32
informant-based cdr
16
dementia
12
cognitive
12
dementia cognitive
12
detecting dementia
12
clinical dementia
8
dementia rating
8
impairment
8
impairment hospitalized
8

Similar Publications

Background: Early identification of pathological α-synuclein deposition (αSynD) may improve understanding of Lewy body disorder (LBD) progression and enable timely disease-modifying treatments.

Objectives: We investigated αSynD using a seed amplification assay and assessed prodromal LBD symptoms in individuals with idiopathic olfactory dysfunction (iOD).

Methods: In this cross-sectional, case-control study, we included iOD participants and normosmic healthy controls (HC) aged 55 to 75 years without diagnoses of dementia with Lewy bodies, Parkinson's disease (PD), or other major neurological disorders.

View Article and Find Full Text PDF

Investigating the impact of hyperbilirubinemia on cognitive dysfunction in adult zebrafish: an in vivo model.

Korean J Anesthesiol

September 2025

Department of Anesthesiology and Pain Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15588, the Republic of Korea.

Background: Despite the well-known effects of elevated bilirubin in neonates, its neurotoxic potential in adults remains uncertain. In perioperative and hepatic disease contexts, transient bilirubin elevations are common; however, their direct contribution to cognitive dysfunction has not been clearly established. This study aimed to determine whether transient bilirubin elevation alone can impair cognition and disrupt blood-brain barrier (BBB) function in adult zebrafish, and to compare these effects with those of liver injury.

View Article and Find Full Text PDF

Antibody Therapies for Alzheimer's Disease: A New Strategy for Targeted Therapy and Blood-Brain Barrier Delivery.

ACS Chem Neurosci

September 2025

Institute of Cell Engineering, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21215, United States.

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive impairment and neuronal loss, with pathological hallmarks including Aβ plaque deposition and tau tangles. At present, the early diagnosis and treatment of AD still face great challenges, such as limited diagnostic methods, difficulty in blood-brain barrier (BBB) penetration, complex disease mechanisms, and lack of highly effective targeted therapies. Antibody drugs have shown broad prospects in the field of AD due to their high specificity, engineering and multifunctional therapeutic potential, include targeted Aβ clearance, tau pathological regulation, imaging probes, and blood biomarkers.

View Article and Find Full Text PDF

Aim: To assess whether the Mini-Mental State Examination, second edition (MMSE-2), scores were associated with the category of functional independence of nursing-home residents and the level of accommodation services they received.

Methods: This cross-sectional study enrolled 248 participants older than 65 residing in five county-owned nursing homes in the city of Zagreb from 2017 to 2019. Cognitive status was assessed with the standard version of the MMSE-2, and the level of functional independence with the modified Barthel scale index.

View Article and Find Full Text PDF

Network Pharmacology of miR-146a-5p as a Potential Anti-Inflammatory Agent in Preventing Alzheimer's Disease.

Curr Alzheimer Res

September 2025

School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, 47500 Subang Jaya, Selangor, Malaysia.

Introduction: Alzheimer's disease is expressed as chronic neuroinflammation in the brain, which results in neuronal dysfunction, aberrant protein folding, and declining cognitive abilities. miR-146a-5p is a potent anti-inflammatory agent that can be used to treat several inflammatory diseases, as well as promote wound healing. Our research aimed to utilize network pharmacology to elucidate the therapeutic potential of miR-146a-5p in treating Alzheimer's disease using a biocomputational approach.

View Article and Find Full Text PDF